Sorafenib

Table 5. Pharmacokinetic variables of gemcitabine and dFdU after 1, 000 mg m2 i.v. doses of gemcitabine alone day 1, cycle 1 ; and in combination day 15, cycle 1 ; with sorafenib after 100, 200, and 400 mg bid doses of sorafenib geometric mean, % CV. High School Student: St. Ignatius College Prepatory, Chicago, Illinois Research Location: University of Illinois at Chicago Relationship Between EPEC-Induced Barrier Function Disruption and Host Cell Death.

Naphylaxis is a severe and immediate Ewan 1998 ; suggested that foods are the hypersensitivity reaction usually to commonest cause of anaphylaxis. Insect food, drugs or insect stings. As Avery venom is the next most common cause. A and Pringle 1995 ; have stated, life-threatening rapidly increasing problem is allergy to latex emergencies are not an everyday occurrence rubber. He suggested that vaccines remain a in general practice, and some conditions such rare cause of anaphylaxis, but drugs causing as anaphylactic shock may occur only a few anaphylaxis include antibiotics, intravenous times in a professional lifetime. The rarity of anaesthetic drugs, aspirin, non-steroidal antiemergencies makes the task of keeping up to inflammatory drugs, intravenous contrast date with best practice a challenge. Avery and media and opioid analgesics. Pringle suggest that regular discussion of upThe following discussion explains how to to-date protocols, regular attendance at recognize anaphylaxis and manage an emerpractical courses and the stocking and gency. The need for staff to prepare themmaintenance of appropriate equipment will selves in advance of such events as highlightall help ensure that general practice ed. professionals can deliver a high quality emergency service. Recognition In the experience of Jane Lambert, who The Resuscitation Council UK ; 2005 ; sugruns a company providing training to GPs gests that there are no universally accepted and practice nurses, resuscitation training is definitions of anaphylactic and anaphylactoid the most commonly requested. Rarely do GPs reactions. The term anaphylaxis is commonly request anaphylaxis training. It is also not used for hypersensitivity reactions typically routine for practice nurses in all areas to mediated by immunoglobulin E IgE ; . attend such training. Anaphylactoid reactions are similar, but do Over recent years, the trend has been to not depend on hypersensitivity. Initial treatupdate community-based nurses annually on ment will be the same. The clinical features of the recognition and management of anaphyanaphylaxis are listed in Table 1. laxis, but there appears to be a lack of such The Resuscitation Council UK ; 2005 ; training among practice staff. also states that reactions vary in severity, and Hogan 2002 ; suggests that the that progress may be rapid, slow, Table 1. Signs increased prevalence of allergy in or in unusual cases ; biphasic. In and symptoms of rare instances manifestations may the community makes it likely anaphylaxis that at some stage most GPs will be delayed by a few hours, or may have to treat a case of acute anapersist for more than 24 hours. Angio-oedema phylaxis. The lack of any consistent presEwan 1998 ; found that little entation of anaphylaxis someUrticaria data on the overall incidence of times makes diagnosis difficult. Dyspnoea anaphylaxis was available. He The Resuscitation Council UK ; Hypotension found a study of cases presenting 2005 ; finds that many patients to the accident and emergency with genuine anaphylaxis do not Rhinitis and conjunctivitis department in Cambridge, which receive appropriate medication. It Abdominal pain, vomiting highlighted that 1 in 1500 patients also suggests that in rare cases and diarrhoea attending the department had patients have been given injecSense of impending doom anaphylaxis with loss of contions of adrenaline inappropriSkin may appear either sciousness or collapse equivalent ately for vasovagal reactions or flushed or pale to 1 in 000 a year in the popupanic attacks. lation ; . They then found that the The Resuscitation Council UK ; Cardiovascular collapse rate almost trebled when systemic continues to urge that, in each From: Resuscitation Council allergic reactions with respiratory case, a full history and examina UK ; , 2005. difficulty were included. tion should be undertaken as soon. NEW HAVEN, CT, July 17, 2006 - VION PHARMACEUTICALS, INC. NASDAQ CAPITAL MARKET: VION ; today announced that Aileen Ryan had joined the Company's senior management team as Vice President, Regulatory Affairs. She will be in charge of global regulatory strategy for the Company's anticancer products and direct the group responsible for interaction between Vion and the U.S. Food and Drug Administration FDA ; and other regulatory agencies worldwide. Ms. Ryan was formerly the head of Global Regulatory Strategy, Oncology for Bayer Pharmaceuticals Corporation. She held this position since 2004. At Bayer, she was responsible for the global regulatory strategy for a portfolio of oncology compounds, including Nexavar sorafenib ; Tablets, Bayer's multi-kinase inhibitor for the treatment of advanced renal cell carcinoma, which was approved by the FDA in December 2005. Prior to Bayer, she was Vice President, Regulatory Affairs for Coley Pharmaceutical Group from 1999 to 2003. Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have Aileen Ryan joining Vion to lead our effort to achieve regulatory approval for our anticancer agent Cloretazine VNP40101M ; worldwide. She has over twenty-five years of experience in the management of regulatory affairs and strategy in the pharmaceutical industry. Her recent experience with the approval of Nexavar in the United States will be invaluable to us." Ms. Ryan commented, "I excited to be joining the management team at Vion. For a company of its size, it has an excellent pipeline of anticancer agents in development, including the late-stage clinical product Cloretazine VNP40101M ; . I look forward to working to advance all of Vion's products, with the goal of improving the care of cancer patients worldwide. Sorafenib BAY 43-9006 ; in patients with advanced renal cell carcinoma RCC ; . J Clin Oncol 2005; 23: LBA4510. 21. EisenT, Ahmad T, Gore ME, et al. Phase I trial of BAY 43-9006 sorafenib ; combined with dacarbazine DTIC ; in metastatic melanoma patients [abstract]. J Clin Oncol 2005; 23: 7508. Flaherty KT, Brose M, Schuchter L, et al. Phase I II trial of BAY 43-9006, carboplatin C ; and paclitaxel P ; demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [abstract]. J Clin Oncol 2004; 22: 7507. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3: 1001 Flaherty KT, Brose M, Schuchter LM, et al. Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma: PFS and response versus BRaf status. Proceedings of the 4th International Symposium on Targeted Anticancer Therapies TAT ; . Ann Oncol 2006; 46: 1110. Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 2006; 106: 375 Santamaria G, Velasco M, Farre X, et al. Power Doppler sonography of invasive breast carcinoma: does tumor vascularization contribute to prediction of axillary status? Radiology 2005; 234: 374 Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors GISTs ; treated with Gleevec imatinib mesylate ; . AJR J Roentgenol 2002; 179: 1059 Lassau N, Lamuraglia M, Leclere J, Rouffiac V. Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents. J Radiol 2004; 85: 704 Lavisse S, Lejeune P, Bissery MC, et al. Early evaluation of the vascular targeting agent AVE 8062A in melanoma tumor-bearing mice using dynamic contrast enhanced-ultrasonography DCE-US ; . Assoc Cancer Res 2006; 47: 233. Armand JP, Loriot Y, Ropert S, et al. Perfusion assessment of tumors by Doppler ultrasonography, a tool for early evaluation of targeted antiangiogenic compounds. Ann Oncol 2006; 17: 21. Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced ultrasound. J Roentgenol 2006; 187: 1267 Lassau N, Lamuraglia M, Vanel D, et al. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 2005; 16: 1054 Lamuraglia M, Lassau N, Chami L, et al. A pilot study using dynamic contrast-enhanced Doppler ultrasound to predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib. Eur J Cancer 2006; 42: 2472 Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 2001 ; 46: 72 8. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965 Dalakas MC, Mock V, Hawkins MJ. Fatigue: definitions, mechanisms, and paradigms for study. Semin Oncol 1998; 25: 48 Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001 ; 19: 265 72. Eggermont AM. Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response. Ann Oncol 2005; 16: 995 Siu LL, Awada A, Takimoto C, et al. Phase I study of oral Raf-1 kinase inhibitor BAY 43-9006 in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol 2003; 22: 828. Kupsch P, Passage K, Richly H, et al. Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors [abstract 3056]. J Clin Oncol 2004; 23: 209. Nicol D, Hii SI, Walsh M, et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 1997; 157: 1482 Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997; 3: 2451 Lara PN, Jr., Quinn DI, Margolin K, et al. SU5416 plus interferon a in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 2003; 9: 4772 Veronese ML, Flaherty KT, Townsend R, et al. Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension. J Clin Oncol Meeting Abstracts ; 2004; 22: 2035. Jacobsen J, Grankvist K, RasmusonT, Ljungberg B. Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev 2002; 11: 245 Gollob J, Richmond T, Jones J, et al. Phase II trial of sorafenib plus interferon-a 2b IFN- 2b ; as first- or second-line therapy in patients pts ; with metastatic renal cell cancer RCC ; . J Clin Oncol Meeting Abstracts ; 2006; 24: 4538. Escudier B, Szczylik C, DemkowT, et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon IFN ; in treatment-naive patients with metastatic renal cell carcinoma mRCC ; . J Clin Oncol Meeting Abstracts ; 2006; 24: 4501.

Gill, R.T., Valdes, J.J. and Bentley, W.E. 2000 ; A comparative study of global stress gene regulation in response to overexpression of recombinant proteins in Escherichia coli. Metabolic Eng. 2, 178-189 and soriatane. It also inhibits several other tyrosine kinases involved in tumor progression, including VEGFR-2, VEGFR-3, PDGFR-, Flt3, c-Kit, and Ret 6, 60 ; . Interestingly sorafenib has been shown to inhibit mutant.
In that it responds to a great variety of drugs at concentrations which result in discreet alterations in cellular function, and there is an apparent correlation between phosporylase activity, rate of glycogenolysis, and the activity of the sympathetic nervous system and sympathomimetic drugs. Since sodium and potassium have an important influence on membrane phenomena, these ions, together with calcium, may also affect these biological systems.85 A study of halothane anaesthesia on such a broad base has been reported by Suutarinen and associates, 86 which gives us a much better idea of the interaction of various metabolites, than would an attempt to draw conclusions from estimations of excess lactate alone. Blood Water See Table VIII ; Besides water loss in the urine, feces, and sweating, the normal active human loses approximately 500 ml. of water as vapour ; from the lungs in 24 hours. Since dogs do not sweat, and because they have a much higher basal metabolism 7 ml. O2 min. kg., as opposed to 4 ml. O2 min. kg. in man ; , they lose a relatively larger amount of water in the urine and from the lungs by both breathing and panting. During the administration of anaesthesia in a non-rebreathing system, the water vapour content of the atmosphere is not available to the lungs, whereas the expired gas is fully saturated with water. It is conceivable, therefore, that if the expired gas from the pulmonary airway contains seven per cent water saturated air at 38 C. ; and a 25-kilogramme dog has a minute ventilation of 10 litres 350-400 ml. kg. min. ; as arranged in these experiments, it is possible to lose in excess of 50 ml. of water during 90 minutes of anaesthesia. The only ready source of water in the lungs in these experiments is the circulating blood, containing 80 per cent water, which would amount to approximatly 1500 ml. water in the circulating blood of a 25-kilogramme dog. The only anaesthetic that appeared to cause an appreciable consistent reduction ~ 4% ; in the wholeblood water was diethyl ether. This reduction would account for a loss of approximately 48 ml. water, assuming the dog's blood volume to be 80 ml. kg. It appears therefore that all of the water that was lost from the blood during the anaesthetic experiments can be accounted for by loss through the lungs. However, there have been other explanations: McAllister and Root showed that during diethyl-ether anaesthesia there is a reduction of plasma volume; 87-88 Stewart and Rourke attributed this haemoconcentration to a shift of fluid out of the circulation into the extracellular fluid space; 65 Robertson and Frazer recently attributed such a shift of water to the movement of sodium and potassium, 89 and Crawford and Guadino showed that there is in fact an expansion of the extracellular fluid volume during the administration of diethyl ether, cyclopropane, and thiopental anaesthesia with nitrous oxide supplementation.90 They also found that the administration of isotonic saline solution as was done in our experiments ; causes a highly variable increase in extracellular fluid. Many homeostatic mechanisms come into play when extra water is lost from the body, and tend to suppress excessive loss of cellular and interstitial water. The and sparfloxacin.

Leukocyte Reduced X Candidates for heart and kidney transplant. 5 and spectinomycin. The intermediate-risk group. Ninety-three percent of patients had had nephrectomy, and 82% cytokine therapy as their prior systemic treatment. An independent committee reviewed the data about the safety and efficacy of sorafenib. An interim analysis had been planned after about 270 patients had died. In April 2005, on the basis of the first PFS analysis by the committee, the patients were unblinded and sorafenib offered to the patients assigned to receive placebo. Because crossover could compromise the end point of survival, the trial was amended to allow a first analysis of overall survival at the start of treatment crossover in May 2005, after 220 deaths had occurred. The median duration of treatment was 23 weeks in the sorafenib group and 12 weeks in the placebo group. Similar proportions of patients discontinued treatment because of adverse events in each group 10% in the sorafenib group and 8% in the placebo group ; . Thirteen percent of patients receiving sorafenib required dose reductions and 21% of patients required dose interruptions because of adverse effects. The median duration of dose interruption was 7 days; the interruptions were mostly due to dermatological events, such as handfoot skin reactions or rash, and gastrointestinal events, such as diarrhea. Other common adverse events were fatigue, alopecia and nausea. Most adverse events were grade 1 or 2 intensity and were self-limiting. Hypertension occurred more frequently in the sorafenib group than in the placebo group, was usually observed in the first cycle of treatment and led to permanent discontinuation in less than 1% of patients. Cardiac ischemia or infarction occurred in 12 3% ; of 451 patients in the sorafenib group compared with 2 less than 1% ; patients treated with placebo p 0.01 ; . The first analysis of overall survival was done immediately before the crossover was allowed, when 220 deaths 41% of the protocol-defined 540 deaths ; had occurred. With a median follow-up of 6.6 months, the median actuarial overall survival was 14.7 months in the placebo group, but had not been reached in the sorafenib arm hazard ratio 0.72; 95% CI 0.540.94; p 0.02 ; . When survival was assessed 6 months later, 216 of 452 patients receiving placebo had switched to sorafenib and 367 deaths had occurred. Median overall survival was 19.3 months in the sorafenib group and 15.9 months in the placebo group hazards ratio 0.77; 95% CI 0.630.95 ; . For both analy.